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Introduction: Synaptic dysfunction and degeneration are central events in Alzheimer’s disease (AD) pathophysiology
that are thought to occur early in disease progression. Synaptic pathology may be studied by examining protein
biomarkers specific for different synaptic elements. We recently showed that the dendritic protein neurogranin (Ng),
including the endogenous Ng peptide 48 to 76 (Ng48–76), is markedly increased in cerebrospinal fluid (CSF) in AD and
that Ng48–76 is the dominant peptide in human brain tissue. The aim of this study was to characterize Ng in
plasma and CSF using mass spectrometry and to investigate the performance of plasma Ng as an AD biomarker.
Methods: Paired plasma and CSF samples from patients with AD (n = 25) and healthy controls (n = 20) were
analyzed in parallel using an immunoassay developed in-house on the Meso Scale Discovery platform and hybrid
immunoaffinity-mass spectrometry (HI-MS). A second plasma material from patients with AD (n = 13) and healthy
controls (n = 17) was also analyzed with HI-MS. High-resolution mass spectrometry was used for identification of
endogenous plasma Ng peptides.
Results: Ng in human plasma is present as several endogenous peptides. Of the 16 endogenous Ng peptides
identified, seven were unique for plasma and not detectable in CSF. However, Ng48–76 was not present in plasma.
CSF Ng was significantly increased in AD compared with controls (P < 0.0001), whereas the plasma Ng levels were
similar between the groups in both studies. Plasma and CSF Ng levels showed no correlation. CSF Ng was stable
during storage at −20°C for up to 2 days, and no de novo generation of peptides were detected.
Conclusions: For the first time, to our knowledge, we have identified several endogenous Ng peptides in human
plasma. In agreement with previous studies, we show that CSF Ng is significantly increased in AD as compared
with healthy controls. The origin of Ng in plasma and its possible use as a biomarker need to be further investigated.
The results suggest that CSF Ng, in particular Ng48–76, might reflect the neurodegenerative processes within the brain,
indicating a role for Ng as a potential novel clinical biomarker for synaptic function in AD.* Correspondence: hlin.johansson-schmidt@neuro.gu.se
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Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by neuropathological changes in the brain,
including extracellular amyloid-β (Aβ) deposits called
plaques as well as neurofibrillary tangles consisting of
hyperphosphorylated tau protein (p-tau) [1,2]. Lower cere-
brospinal fluid (CSF) levels of the 42–amino acid–long Aβ
peptide Aβ1–42, reflecting the plaque pathology, together
with increased concentrations of total tau (t-tau) and
p-tau, reflecting neurodegeneration and tangle pathology,
respectively, are today considered the core CSF bio-
markers for AD [3].
A central event in AD pathology is synaptic dysfunction
and degeneration [4]. Synaptic loss correlates with cogni-
tive decline and is more associated with the degree of
dementia compared to plaques and tangles [5-8], especially
within certain areas of the brain, such as the hippocampus
[7,9]. Furthermore, synaptic loss has been identified as an
early event in the disease progression, as well as the under-
lying cause of the progressive cognitive deterioration as the
disease advances [4]. Thus, synaptic markers are promising
tools for early AD diagnosis. Moreover, such biomarkers
could also be used to monitor disease progression and play
an important role in the evaluation of novel disease modi-
fying therapeutics.
Neurogranin (Ng) is a postsynaptic protein with a crit-
ical role in long-term potentiation, where it regulates the
levels of calmodulin in response to intracellular calcium
levels after neuronal excitation [10-12]. In the brain, Ng
is localized to dendritic spines of neurons within associa-
tive cortical areas, including the hippocampus, amygdala
and cerebral cortex [11,13]. Studies on rodents have shown
that both the Ng mRNA and total protein levels are
age-dependently decreased in several regions of the brain,
including the hippocampus [14]. In addition, in situ
hybridization studies on the human brain have shown
that the Ng mRNA is selectively translocated to dendrites
and that such translocation is impaired in the cortex of
patients with AD [15].
Recently, we generated three monoclonal anti-Ng
antibodies with epitopes near the C-terminal part of the
protein [16]. By immunoprecipitation using the anti-
bodies Ng2 and Ng3, followed by high-resolution mass
spectrometry (MS), we identified several endogenous
Ng peptides in both brain tissue and CSF. A third
monoclonal antibody, Ng7, was used as a capturing
antibody in an enzyme-linked immunosorbent assay
(ELISA) developed in-house for measuring CSF Ng. In
three independent cohorts, we showed increased CSF
Ng levels in AD CSF as compared with healthy controls.
Using hybrid finity MS (HI-MS), we also showed that
the endogenous Ng peptide 48 to 76 (Ng48–76) was sig-
nificantly increased in AD CSF as compared with con-
trols [16].If a synaptic marker reflecting the ongoing synaptic
degeneration in the central nervous system (CNS) could
be identified in blood or plasma, it would be a very valu-
able clinical tool because CSF sampling is considered to
be a somewhat more invasive procedure. In addition, sim-
ple and repeated sampling would also be made possible,
allowing for dynamic changes to be measured over time at
a regular clinic. Therefore, in this study of paired plasma
and CSF samples, we aimed to first characterize Ng in
plasma using MS and then investigate whether plasma Ng
is a marker of synaptic degeneration in AD.
Using MS, we show—for the first time, to our knowl-
edge—that Ng is expressed as a variety of endogenous Ng
peptides in human plasma. Although plasma Ng was not
found to differ between AD patients and healthy controls,
we replicated the previous finding of increased CSF Ng in
the AD group using an in-house assay developed on the
Meso Scale Discovery (MSD) platform. Finally, we also
show that CSF Ng is stable during storage and that no pep-
tides are generated de novo. The endogenous peptide Ng48–
76, which in our previous study was found to be significantly
increased in both patients with AD and individuals with
prodromal AD, was not found in plasma. The findings pre-
sented in the present study imply that CSF Ng might reflect
the ongoing neurodegenerative processes within the CNS,
indicating a role for Ng, and in particular Ng48–76, as a po-
tential novel clinical biomarker for synaptic function in AD.
Methods
Anonymized plasma samples collected in the routine work-
flow at the Neurochemistry Laboratory at Sahlgrenska
University Hospital, Mölndal, Sweden, were used for
method development, as approved by the ethics commit-
tee at the University of Gothenburg.
Patients in paired cerebrospinal fluid and plasma study
The paired CSF and plasma study included 25 AD patients
(mean age: 76 ± 8 years) and 20 control subjects without
dementia (mean age: 54 ± 14 years) (see Table 1 for demo-
graphics and biomarker characteristics). The AD group
consisted of patients with probable AD with a high level of
evidence of an AD pathophysiologic process and patients
with mild cognitive impairment with a high likelihood of an
underlying AD process. In the rest of this article, this group
is called AD. The patients were recruited in Erlangen,
Germany, and each underwent a thorough clinical investi-
gation, including a medical history as well as a physical,
neurological and psychiatric examinations. The diagnosis
of AD was made according to the National Institute of
Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders association
(NINCDS-ADRDA) criteria [17]. No patient with AD
had a family history of dementia suggestive of autosomal
dominant AD. The control group consisted of patients
Table 1 Demographic and clinical characteristics of
subjects included in the study 1 and 2a
Control AD
Study 1
(paired plasma + CSF)
n = 20 n = 25
Sex, n, female/male
(% female)
12/8 (60) 14/11 (56)
Age at LP, yr 54 (41 to 63) 76 (71 to 78)b
CSF Aβ1–42, pg/ml 1,399 (1189 to 1702) 709 (588 to 897)b
CSF Aβ1–42/Aβ1–40 ratio 0.094 (0.079 to 0.104) 0.033 (0.028 to 0.042)b
CSF t-tau, pg/ml 185 (136 to 254) 580 (425 to 655)b
CSF p-tau, pg/ml 35 (27 to 45) 89 (78 to 105 to 126)b
CSF Ng, pg/ml (MSD) 291 (251 to 438) 620 (521 to 818)b
Plasma Ng, pg/ml (MSD) 47,451 (21,904 to
90,320)
36,525 (25,324 to
57,715)
Plasma, pg/ml (HI-MS) 21,698 (13,401 to
106,954)
25,644 (17,262 to
53,900)
Study 2 (plasma) n = 17 n = 13
Sex, n, female/male
(% female)
9/17 (53) 9/13 (69)
Age at LP, yr 58 (53 to 68) 78 (69 to 80)b
CSF Aβ1–42, pg/ml 875 (580 to 940) 330 (268 to 415)
b
CSF t-tau, pg/ml 300 (210 to 348) 690 (605 to 980)b
CSF p-tau, pg/ml 48 (40 to 61) 110 (77 to 160)b
aAβ, Amyloid-β; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; HI-MS, Hybrid
immunoaffinity-mass spectrometry; LP, lumbar puncture;MSD,Meso Scale Discovery;
Ng, Neurogranin; p-tau, Phosphorylated tau; t-tau, Total tau. The values
presented are median (interquartile range). bP < 0.001 vs. controls.
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The clinical diagnoses (including neuroimaging and
neuropsychology) were combined with the results of the
following CSF biomarkers: Aβ1–42, Aβ1–40 (to calculate the
Aβ42/40 concentration ratio), t-tau and p-tau181. The sub-
jects were included in the study only if the clinical, neuro-
imaging and neuropsychological diagnoses were in
accordance with the neurochemical findings as described
elsewhere [18]. There were no patients included in the
study with a completely negative AD biomarker pattern.
Control subjects had all biomarkers within normal ranges.
CSF t-tau, p-tau, Aβ1–40 and Aβ1–42 concentrations were
determined using established ELISA methods as described
elsewhere [18]. All analyses were performed at the Univer-
sitätsklinikum Erlangen. The study was conducted accord-
ing to the provisions of the Declaration of Helsinki. All
subjects gave their written informed consent for the use of
their clinical data for research purposes, as approved by the
ethics committee of the Universitätsklinikum Erlangen.
Patients and plasma samples included in the verification
study
Plasma samples were collected from 13 patients with AD
(mean age: 78 ± 7 years) and 17 individuals withoutdementia (controls; mean age: 58 ± 9 years) at the Mem-
ory Clinic, Skåne University Hospital, Sweden (see Table 1
for full biomarker characteristics and demographics). The
individuals underwent brain imaging, routine laboratory
testing and neurological, psychiatric and cognitive exami-
nations. Patients diagnosed with AD fulfilled the dementia
criteria of the Diagnostic and Statistical Manual of
Mental Disorders, Third Edition, Revision [19], and the
criteria for probable AD as defined by NINCDS-ADRDA
[17]. The control individuals without dementia experi-
enced subjective cognitive symptoms at baseline, but
thorough clinical investigation as well as clinical follow-up
revealed that the patients were not affected by a dementia
disorder or a neurological disease. CSF t-tau, p-tau and
Aβ1–42 concentrations were determined using established
ELISA methods as described elsewhere [16]. All ana-
lyses were performed at the Clinical Neurochemistry
Laboratory at the Sahlgrenska University Hospital, Mölndal,
Sweden. All individuals gave their informed consent to
participate in research before their samples were stored
in a biobank. A passive consent procedure was then
used whereby consent for retrospective use of banked
samples and basic data was assumed if individuals did
not actively retract permission, as instructed in local press
advertisements. This study procedure was approved by
the local ethics committee at Lund University, Sweden.
Meso Scale Discovery neurogranin assay
The monoclonal mouse antibody Ng7, with an epitope
including amino acids 52 to 65 [16], was used as a cap-
turing antibody and was coated on QUICKPLEX 96-well
plates (Meso Scale Discovery (MSD), Rockville, MD, USA)
at a final concentration of 2.0 μg/ml (40 μl/well) in
phosphate-buffered saline (PBS), followed by incubation
overnight at room temperature (RT). Before being coated
with the capturing antibody, the plates were washed once
with 150 μl of PBS. After the plates were washed with
300 μl of PBS containing 0.05% Tween 20 (PBS-Tween)
four times for 30 seconds each time, the remaining
protein-binding sites were blocked with 5% MSD Blocker
A solution (150 μl/well; Meso Scale Discovery) for 1 hour
at RT and subsequently washed again with 300 μl of
PBS-Tween four times for 30 seconds each time. Then
the full-length Ng calibrators with concentrations ran-
ging between 31.3 and 4,000 pg/ml (1:2 dilution; CSF
samples) or 31.3 to 23,000 pg/ml (1:3 dilution; plasma
samples), blanks and samples (50 μl/well) were incu-
bated in duplicate together with the detecting antibody,
polyclonal Ng anti-rabbit antibody (ab23570; Upstate
Biotechnology, Lake Placid, NY, USA) diluted 1:20,000
in 0.1% bovine serum albumin (BSA) in PBS-Tween over-
night at RT (50 μl/well). Plasma samples were diluted 1:40
in PBS. After washing four times for 30 seconds each
time in PBS-Tween, a MSD SULFO-TAG goat anti-rabbit
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tion 0.5 μg/ml diluted in 0.1% BSA in PBS-Tween, was
added and incubated for 2 hours at RT while being shaken
at 700 rpm. After washing with 300 μl of PBS-Tween four
times for 30 seconds each time, 150 μl of 2× MSD Read
Buffer T with surfactant (Meso Scale Discovery) were used
for immediate reading with a QUICKPLEX SQ 120 reader
(Meso Scale Discovery). A fitted four-parameter logistic
model with relative weighting (1/y2) was used as the
calibration curve, and the blank was included as zero
concentration of Ng. All samples were analyzed without
knowledge of clinical diagnosis.
Immunoprecipitation/matrix-assisted laser desorption/
ionization time-of-flight/time-of-flight analysis
To minimize nonspecific binding of other proteins dur-
ing the immunoprecipitation, all plasma samples were
pretreated twice with 20 μl of Novex Dynabeads Protein
G (Life Technologies, Carlsbad, CA, USA) per milliliter
of plasma and incubated for 1 hour at RT before the
beads were magnetically removed as described previously,
with some modifications [20]. HI-MS analysis of Ng pep-
tides was performed as described elsewhere [16]. In brief,
4 μg of the monoclonal anti-Ng antibodies Ng2 and Ng3
were separately added to 25 μl of Dynabeads M-280 sheep
anti-mouse immunoglobulin G (Life Technologies) and
cross-linked as previously described [21]. Beads coated
with Ng2 and Ng3 were used for immunoprecipitation of
plasma to which n-octyl-β-D-glucopyranoside (10%, end
concentration 0.1%; Fluka Chemie, Buchs, Switzerland) had
been added. The beads and sample were transferred to a
KingFisher magnetic particle processor (polypropylene tubes;
Thermo Scientific, Waltham, MA, USA) for automatic wash-
ing and elution of the Ng peptides and protein. Eluted Ng
was collected and dried in a vacuum centrifuge and redis-
solved in 5 μl of 0.1% formic acid (FA) in 20% acetonitrile
and subsequently analyzed using an ultrafleXtreme matrix-
assisted laser desorption/ionization (MALDI) time-of-flight/
time-of-flight (TOF/TOF) MS (Bruker Daltonics, Bremen,
Germany). All solvents used were of high-performance
liquid chromatography (HPLC) quality.
In both the paired cohort and validation study where
MALDI-TOF/TOF MS was used, the custom Ng peptide
RKKIKSGERGRKGPGPGGPGGAGVARGGAGGGP (cor-
responding to Ng43–75), with glycine labeled with double
13C (theoretical molecular mass: 3,011 Da; CASLO,
Lyngby, Denmark), was added to the plasma prior to
sample preparation and was used as an internal standard.
Samples were analyzed blinded (that is, without knowledge
of clinical diagnosis).
High-resolution tandem mass spectrometry
The identities of the Ng peptides were confirmed using
a top-down approach as previously described [22], butwith updated instrumentation. Briefly, analysis was per-
formed using nanoflow liquid chromatography (Dionex
UltiMate 3000; Thermo Scientific) coupled to an electro-
spray ionization Q Exactive Hybrid Quadrupole Orbitrap
tandem mass spectrometer (Thermo Scientific). An Ac-
claim PepMap 100 C8 trap column (length: 20 mm; inner
diameter: 75 μm; particle size: 3 μm; pore size: 100 Å
(Thermo Scientific)) was used for online desalting, and a
reversed-phase Acclaim PepMap rapid separation liquid
chromatography column (length: 500 mm, inner diameter:
75 μm; particle size: 2 μm; pore size: 100 Å (Thermo
Scientific)) was used for high-resolution separation. Mobile
phases were 0.1% aqueous FA (v/v) (A) and 0.1% FA in
84% acetonitrile in water (v/v) (B). The separation was per-
formed at a flow rate of 150 nl/min by applying a linear
gradient of 3% to 40% B for 50 minutes. A column oven
was used and set to 40°C. All solvents used were of HPLC
quality. The Q Exactive system was used in positive ion
mode to acquire full-scan spectra in the 300 to 1,200
mass-to-charge (m/z) ratio range at a resolution setting of
70,000. Subsequent tandem mass spectra (MS/MS) were
produced using the higher-energy collisional dissociation
fragmentation cell and acquired at the same resolution set-
ting. An inclusion list was employed to ensure that we ob-
tained MS/MS data of the compounds of interest. Mass
spectral raw files were then charge-deconvoluted by using
Mascot Distiller software (Matrix Science, Boston, MA,
USA) and subsequently submitted to a Mascot database
search (Matrix Science).Degradation of neurogranin in plasma and cerebrospinal
fluid at room temperature
Plasma and CSF samples were depleted of native Ng by
three consecutive immunoprecipitations before full-length
recombinant Ng (1,000 pg/ml) was added to the samples,
followed by 24-hour incubation at RT. After the incuba-
tion, samples were analyzed by HI-MS to screen for deg-
radation products from the full-length Ng protein in the
form of newly formed Ng peptides.Cerebrospinal fluid neurogranin storage stability
assessment
Pooled CSF samples with or without a stabilizing agent
(sodium azide at a final concentration of 0.1% in samples),
were kept at RT, 4°C or −20°C for 1 to 7 days before they
were placed in long-term storage at −80°C pending ana-
lysis. As a reference sample, a freshly prepared aliquot,
with or without stabilizer, was stored at −80°C on the day
of the preparation (that is, day 0). All other samples were
normalized against the Ng content of the respective refer-
ence sample for either group. Ng content was analyzed by
MSD.
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For statistical analysis, Prism 6 for Windows software
(GraphPad Software, La Jolla, CA, USA) was used. Be-
cause biomarker values were skewed, nonparametric tests
were used. Differences between groups were assessed
using the Mann–Whitney U test, and significance was de-
termined at P < 0.05. Correlations were determined using
Spearman’s correlation.
Results
Characterization of plasma neurogranin
Plasma Ng was characterized using MALDI-TOF/TOF
and high-resolution MS/MS. Several short C-terminal
peptides were repeatedly detected by MALDI-TOF/TOF,
and 16 of these were independently verified and identified
by high-resolution MS/MS (Figure 1A and Table 2). Of
these, seven had not previously been detected in brainFigure 1 Hybrid immunoaffinity-mass spectrometry characterization of plasm
human plasma repeatedly detected several short C-terminal peptides. *Pe
tissue. ‡Nonspecific binding of other plasma proteins to magnetic beads. (B)
neurogranin (Ng) is present in plasma. *Peak corresponding to the theoretissue or CSF [16]. A summary of all Ng peptides that
have been identified using MS in plasma, CSF and brain
tissue can be found in Additional file 1: Table S1. A
cluster of peaks at the m/z ratio corresponding roughly
to full-length Ng (theoretical mass: 7,618 Da) was
detected (Figure 1B), indicating that the protein most
likely is subjected to several posttranslational modifica-
tions; however, these have yet to be identified.
Clinical validation of paired plasma and cerebrospinal
fluid samples
Paired plasma and CSF samples from patients with AD
and controls were analyzed for Ng levels to investigate
the potential of plasma Ng as a novel biomarker. Plasma
samples were analyzed in parallel by using an MSD plat-
form assay and HI-MS targeting both the shorter en-
dogenous peptides and full-length Ng. Using HI-MS,a neurogranin. (A) Hybrid immunoaffinity-mass spectrometry analysis of
ptides found only in plasma and not in cerebrospinal fluid or brain
A cluster of peaks roughly corresponding to the mass of full-length
tical mass of full-length Ng (7,618 Da). m/z, Mass-to-charge ratio.
Table 2 Identified plasma neurogranin peptides by high-resolution mass spectrometrya
Calculated mass (Da) Theoretical mass (Da) Deviation (ppm) Confirmed sequence Number of y-ions Number of b-ions
1,899.98 1,899.98 −1.3 52 to 75b 1 11
2,203.24 2,203.24 1.7 43 to 65b 1 14
2,217.24 2,217.25 −1.8 44 to 67b 2 8
2,242.14 2,242.14 −0.1 49 to 75 5 12
2,329.18 2,329.17 1.0 48 to 75 10 20
2,373.34 2,373.35 −1.0 43 to 67b 0 6
2,570.36 2,570.35 1.8 46 to 75 10 17
2,698.45 2,698.45 0.1 45 to 75 12 19
2,826.54 2,826.54 −2.4 44 to 75 19 21
2,982.64 2,982.64 −1.7 43 to 75 21 8
3,053.69 3,053.68 2.9 42 to 75b 18 6
3,085.61 3,085.62 −4.3 44 to 78 6 12
3,184.73 3,184.72 2.7 41 to 75 14 4
3,241.72 3,241.73 −1.6 43 to 78 19 13
3,378.81 3,378.80 1.8 39 to 75b 8 2
3,534.91 3,534.90 1.7 38 to 75b 11 10
aMass deviation is displayed in parts per million (ppm). bPeptides found only in plasma and not in cerebrospinal fluid or brain tissue.
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and quantified, but none were found to differ signifi-
cantly between the groups. Concentrations of the
most abundant plasma Ng peptide, Ng43–75, which
was present in all samples, are displayed in Figure 2A.
This finding was replicated by HI-MS analysis in a
second independent plasma material, where, once
again, none of the peptides differed between patients
with AD and healthy controls. Concentrations of
Ng43–75 obtained in the validation study are dis-
played in Figure 2B. The peaks at the mass range of
full-length Ng (Figure 1B) were also investigated, but
no significant difference was obtained between
patients with AD and healthy controls (data not
shown). In agreement with this, MSD analysis of
plasma Ng did not reveal any quantitative differences
between the groups (Figure 2C).
In contrast, MSD analysis of the CSF samples
showed a marked increase of Ng in patients with AD
(P < 0.0001) (Figure 2D). As the control group was sig-
nificantly younger than the AD group in both studies
(see Table 1), we also tested for a correlation between
CSF Ng and age, but no such association was found in
the paired cohort (AD group: P = 0.667, rs = −0.1;
control group: P = 0.11, rs = −0.37) or in the validation
study (AD group: P = 0.258, rs = 0.34; control group: P
= 0.77, rs = −0.08). No correlation between CSF and
plasma Ng was found in the paired cohort (P = 0.83,
rs = 0.0334). Owing to the large CSF volume needed for
HI-MS analysis (1 ml), the CSF samples were analyzed
only by MSD.Neurogranin storage stability and degradation in
cerebrospinal fluid and plasma
With the purpose of investigating the stability of CSF Ng
during storage, CSF was kept at RT, 4°C or −20°C with
or without the addition of a stabilizer for between 1 and
7 days before it was stored at −80°C pending analysis.
The samples were analyzed using the MSD Ng assay,
and all values were normalized against a reference sample,
which was stored at −80°C on the day of preparation. The
CSF Ng levels were stable at RT for 2 days, after which
the concentration dropped to around 70% compared
with the day of preparation. Samples kept at either 4°C
or −20°C were both stable for all time points investi-
gated (Figure 3A). Similar results were obtained when a
stabilizing agent was added (Figure 3B).
To address the question whether any degradation of
Ng occurs in CSF and plasma, CSF and plasma samples
that had been depleted of all native Ng by immunoprecipi-
tation using Ng2 and Ng3 were spiked with full-length Ng
(1,000 pg/ml) and incubated at RT for 24 hours. The sam-
ples were then analyzed for newly generated Ng peptides
using HI-MS. In CSF, no Ng peptides generated de novo
could be detected in the spiked samples after the incuba-
tion (data not shown). In contrast, 14 Ng peptides were
detected in the spiked plasma samples, indicating that Ng
is degraded in plasma (Additional file 2: Table S2).
Discussion
In this study, we characterized the Ng content in plasma
and investigated the potential of plasma Ng as a biomarker
for AD. We also addressed the stability of CSF Ng during
Figure 2 Scatterplots displaying the results from hybrid immunoaffinity-mass spectrometry and Meso Scale Discovery analysis of plasma and cerebro-
spinal fluid samples. (A) Scatterplot of plasma concentrations of the most abundant neurogranin (Ng) peptide 43 to 75 (Ng43–75), in samples from
the paired cohort obtained by hybrid immunoaffinity-mass spectrometry (HI-MS). (B) Scatterplot of plasma Ng43–75 concentrations in samples
from the verification study obtained by HI-MS. (C) Scatterplot of plasma Ng levels obtained by Meso Scale Discovery (MSD) in samples from
the paired cohort. (D) Scatterplot of cerebrospinal fluid Ng levels obtained by MSD. The data presented are medians and interquartile ranges.
AD, Alzheimer’s disease; Co, Control.
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both CSF and plasma.
In total, we identified 16 endogenous Ng peptides in
plasma. We also show that full-length Ng most likely is
present, but mostly in posttranslationally modified forms.
Of the endogenous plasma peptides, seven had not been
detected previously in either brain tissue or CSF [16].
Thus, they seem to be plasma-specific. As we have now
performed HI-MS analysis of Ng peptides in more than 75
plasma samples in total and the plasma-specific peptides
have been present in all of these, we can conclude that
these are consistently found in plasma and are thus most
likely not caused by the preanalytical handling,
In a previous study, we showed increased CSF Ng levels
in AD using ELISA [16]. In the same study, using MS, we
also found that, of the endogenous Ng peptides examined,
Ng48–76 showed the most pronounced increase in AD CSF
compared with controls. Importantly, Ng48–76 was also
found to be the dominant peptide in AD brain tissue [16],
but this peptide was not found in plasma (Table 2). These
data suggest that this particular peptide most likely is
brain-specific. Furthermore, there are also peptides that
are unique for plasma as well as for CSF and brain tissue
(Additional file 1: Table S1). Thus, Ng peptides detected
in CSF may specifically reflect ongoing neurodegenerative
processes within the brain and are most likely not in-
fluenced by Ng peptides produced in the periphery,indicating that they may have valid clinical relevance.
Further supporting CSF Ng as an AD marker are the
discoveries that the plasma Ng levels did not differ be-
tween AD and controls (Figure 2A, B and C) and that
there was a lack of correlation between CSF and plasma
Ng content.
In a series of experiments designed to test the stability
of Ng in plasma, we show that recombinant full-length
protein incubated in plasma, depleted of native Ng, is
metabolized into a variety of fragments (Additional file
2: Table S2), probably by some of the proteases present
in plasma. Five of the detected degradation fragments
most likely correspond to endogenous peptides that
were identified in native plasma samples, and, in
addition to those, we also detected a number of peaks
that most likely correspond to other Ng peptides that
have not been seen in their native counterparts (Add-
itional file 2: Table S2). Also, four of the Ng peptides
found only in plasma were not generated after incubation
of full-length Ng in Ng-depleted plasma, thus indicating
that they are not an artefact of sample handling. This indi-
cates that there are several enzymes present in plasma that
are capable of cleaving Ng. As the peptide patterns of
native plasma Ng and degraded full-length Ng differ,
this might point toward differences regarding the en-
zymes in freeze–thawed plasma samples and enzymes in
plasma in vivo with regard to activity and/or specificity.
Figure 3 Analysis of cerebrospinal fluid neurogranin storage stability.
Normalized cerebrospinal fluid neurogranin (Ng) concentrations in
samples without (A) or with (B) the addition of a stabilizing agent.
Samples were kept at room temperature (RT), 4°C or −20°C for
between 1 and 7 days before transfer to storage at −80°C pending
analysis. Samples were normalized to day 0, with or without stabilizer.
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ent factors, such as pH or storage stability. However, a
characterization of the active enzymes in plasma after −80°C
storage that are capable of cleaving full-length Ng to
generate the peptides observed in such samples is be-
yond the scope of this article.
Ng48–76 was neither naturally occurring (Table 2) nor
generated after incubation of full-length Ng in the
plasma samples investigated (Additional file 2: Table S2).
Therefore, it is unlikely that this specific peptide is pro-
duced in the periphery. These findings indicate that
the enzyme responsible for the formation of Ng48–76 is
present only in the brain or at least is not active in ei-
ther CSF or plasma. This hypothesis is further supported
by the fact that, though there are three Ng peptides in
CSF that end with amino acid 76 (Additional file 1:
Table S1), neither these endogenous peptides (Table 2)
nor fragments generated from recombinant full-length
protein (Additional file 2: Table S2) were found in plasma.
The enzymes responsible for the different cleavages of Ng
remains to be identified.
Compared with CSF, plasma Ng concentration in paired
samples was around 100 times higher (Figure 2C and D).Studies have shown that Ng is expressed in the periphery
in the spleen, bone marrow, platelets and lung tissue
[11], which may contribute to the high concentration in
plasma.
Limitations of both studies are their small sample size
and that healthy control subjects were significantly younger
than the AD patient groups (P < 0.001) (Table 1). However,
considering that no difference in plasma Ng was found be-
tween the groups in either cohort and that increased CSF
Ng in AD has been shown before in age-matched groups
[16], we believe that the age difference between the groups
did not affect the results of this study. Also, we did not find
any correlation between age and Ng concentration in ei-
ther plasma or CSF.Conclusions
The present study shows that Ng is present in plasma at
high concentrations, both as posttranslationally modified
full-length protein and as a number of endogenous pep-
tides. The previously reported difference in Ng levels in
CSF between controls and AD patients is a consistent
finding that is not reflected in the plasma. The most im-
portant discoveries are that there is no degradation of
full-length Ng or de novo formation of peptides in CSF
and that CSF Ng is stable for storage at – 20°C, as well
as that there are no native plasma Ng peptides ending
with amino acid 76. This suggests that CSF Ng, especially
Ng48–76, might reflect ongoing neurodegenerative processes
within the brain, indicating a role for Ng as a potential
novel clinical biomarker for synaptic function in AD.Additional files
Additional 1: Table S1. Summary of all Ng peptides identified by MS/
MS in human brain tissue, CSF and plasma. Microsoft Excel 97–2003
worksheet (.xls). A complete list of all endogenous Ng peptides identified
by MS/MS in human brain tissue, CSF and plasma.
Additional 2: Table S2. Newly formed Ng peptides in plasma incubated
with recombinant full-length Ng. Microsoft Excel 97–2003 worksheet
(.xls). Plasma samples were depleted of native Ng by three consecutive
immunoprecipitations before full-length recombinant Ng (1,000 pg/ml)
was added to samples, followed by 24-hour incubation at RT. After the
incubation, the samples were analyzed by HI-MS to screen for newly formed
Ng peptides.Abbreviations
Aβ: Amyloid-β; AD: Alzheimer’s disease; BSA: Bovine serum albumin;
CNS: Central nervous system; CSF: Cerebrospinal fluid; ELISA: Enzyme-linked
immunosorbent assay; FA: Formic acid; HI-MS: Hybrid immunoaffinity-mass
spectrometry; HPLC: High-performance liquid chromatography;
MALDI: Matrix-assisted laser desorption/ionization; MS: Mass spectrometry;
MS/MS: Tandem mass spectrometry; m/z: Mass-to-charge ratio;
Ng: Neurogranin; NINCDS-ADRDA: National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association; PBS: Phosphate-buffered saline; ppm: Parts per million;
p-tau: Phosphorylated tau; RT: Room temperature; TOF/TOF: Time-of-flight/
time-of-flight; t-tau: Total tau.
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